Top

International Journal of Clinical Oncology

Published in:

01-10-2014 | Original Article

Subcellular localization of Mdm2 expression and prognosis of breast cancer

Authors: Hyung Seok Park, Ji Min Park, Seho Park, Junghoon Cho, Seung Il Kim, Byeong-Woo Park

Published in: International Journal of Clinical Oncology | Issue 5/2014

Abstract

Background

Mouse double minute 2 (Mdm2) is a negative regulator of the tumor suppressor p53. The p53–Mdm2 pathway may play a role in cancer development and prognosis, although the role of p53–Mdm2 in breast cancer remains unclear.

Methods

p53 and Mdm2 expressions were determined by immunohistochemistry of tissue microarrays of 865 breast cancer patients who underwent surgery. Clinicopathological characteristics and survival data were analyzed. Mdm2 expression was categorized into four groups: negative, cytoplasm positive, nucleus positive, and concurrent nuclear and cytoplasm positive (N+&C+).

Results

Negative, cytoplasm-positive, nucleus-positive, and N+&C+ expressions of Mdm2 were observed in 59.2, 10.9, 27.8, and 2.1 % of patients, respectively. The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and progesterone receptors, HER2 positivity, high Ki-67 index, p53 positivity, and triple negative breast cancer. p53-positive tumors showed poorer overall survival than p53-negative tumors. The nucleus-positive and N+&C+ groups showed poorer disease-free survival than the negative and cytoplasm-positive groups. In multivariate analysis, nuclear Mdm2 expression including the N+&C+ group was significantly related to poor prognosis.

Conclusions

Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.

Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923PubMedCrossRef

Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137:413–431PubMedCrossRef

O’Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300PubMed

Scata KA, El-Deiry WS (2007) p53, BRCA1 and breast cancer chemoresistance. Adv Exp Med Biol 608:70–86PubMedCrossRef

Fang S, Jensen JP, Ludwig RL et al (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945–8951PubMedCrossRef

Oliner JD, Kinzler KW, Meltzer PS et al (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83PubMedCrossRef

Haupt Y, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299PubMedCrossRef

Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303PubMedCrossRef

Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565–1569PubMedPubMedCentral

10.

Steinman HA, Burstein E, Lengner C et al (2004) An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279:4877–4886PubMedCrossRef

11.

Brekman A, Singh KE, Polotskaia A et al (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res 13:R3PubMedCrossRefPubMedCentral

12.

Sanchez M, Picard N, Sauve K et al (2013) Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene 32:117–126PubMedCrossRef

13.

Kim K, Burghardt R, Barhoumi R et al (2011) MDM2 regulates estrogen receptor alpha and estrogen responsiveness in breast cancer cells. J Mol Endocrinol 46:67–79PubMedPubMedCentral

14.

Marchetti A, Buttitta F, Girlando S et al (1995) mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175:31–38PubMedCrossRef

15.

Karray-Chouayekh S, Baccouche S, Khabir A et al (2011) Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma. Acta Histochem 113:508–513PubMedCrossRef

16.

Abdel-Fatah TM, Powe DG, Agboola J et al (2010) The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 220:419–434PubMed

17.

Bueso-Ramos CE, Manshouri T, Haidar MA et al (1996) Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat 37:179–188PubMedCrossRef

18.

Hori M, Shimazaki J, Inagawa S et al (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71:77–83PubMedCrossRef

19.

Vestey SB, Sen C, Calder CJ et al (2004) p14ARF expression in invasive breast cancers and ductal carcinoma in situ–relationships to p53 and Hdm2. Breast Cancer Res 6:R571–R585

20.

Hori M, Shimazaki J, Inagawa S et al (2000) Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement. Pathol Int 50:786–792PubMedCrossRef

21.

Lukas J, Gao DQ, Keshmeshian M et al (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61:3212–3219PubMed

22.

Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9–15PubMedCrossRef

23.

Baunoch D, Watkins L, Tewari A et al (1996) MDM2 overexpression in benign and malignant lesions of the human breast. Int J Oncol 8:895–899PubMed

24.

Choschzick M, Heilenkotter U, Lebeau A et al (2010) MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. Cancer Biomark 8:53–60PubMed

25.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

26.

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRefPubMedCentral

27.

Park S, Park HS, Koo JS et al (2012) Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 118:914–923PubMedCrossRef

28.

Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCrossRefPubMedCentral

29.

Carter S, Bischof O, Dejean A et al (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9:428–435PubMedCrossRef

30.

Al-Kuraya K, Schraml P, Torhorst J et al (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534–8540PubMedCrossRef

31.

Galmarini CM, Clarke ML, Falette N et al (2002) Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97:439–445PubMedCrossRef

32.

Nishida T, Yamada Y (2011) The nucleolar SUMO-specific protease SMT3IP1/SENP3 attenuates Mdm2-mediated p53 ubiquitination and degradation. Biochem Biophys Res Commun 406:285–291PubMedCrossRef

33.

O’Keefe K, Li H, Zhang Y (2003) Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 23:6396–6405PubMedCrossRefPubMedCentral

34.

Muller S, Hoege C, Pyrowolakis G et al (2001) SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol 2:202–210PubMedCrossRef

35.

Melchior F, Hengst L (2000) Mdm2-SUMO1: is bigger better? Nat Cell Biol 2:E161–E163

36.

Wang H, Ma X, Ren S et al (2011) A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 10:69–79PubMedCrossRefPubMedCentral

37.

Maeda T, Hobbs RM, Merghoub T et al (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433:278–285PubMedCrossRef

Title: Subcellular localization of Mdm2 expression and prognosis of breast cancer
Authors: Hyung Seok Park
Ji Min Park
Seho Park
Junghoon Cho
Seung Il Kim
Byeong-Woo Park
Publication date: 01-10-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0639-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Prognostic predictors and spread patterns in adult ovarian granulosa cell tumors: a multicenter long-term follow-up study of 108 patients

A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age

Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005–2009 and a comparison with those treated in 1985–2004

Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma

Isomorphic red blood cells using automated urine flow cytometry is a reliable method in diagnosis of bladder cancer

Changing patterns in thyroid cancer incidence and mortality in the Slovak Republic by histological type and age

Keynote webinar | Spotlight on antibody–drug conjugates in cancer